Articles tagged with Alzheimer Disease
The Cleveland Clinic has received two grants totaling $4.6 million to investigate the therapeutic potential of lenalidomide in early-stage Alzheimer's disease. The studies aim to determine if lenalidomide safely reduces inflammatory biomarkers and improves cognition in patients with mild cognitive impairment.
Researchers at Rensselaer Polytechnic Institute are using a $233,776 NIH grant to study the gamma-secretase enzyme responsible for producing Amyloid-Beta 42 peptide in brain cells. The goal is to identify novel mechanisms and targets for future Alzheimer's therapeutics.
A study by University of Liège researchers links increased tau protein levels in the brainstem to higher cortical excitability, a hallmark of Alzheimer's disease. The findings suggest that measuring cortical hyperexcitability could help identify people at risk before cognitive symptoms appear.
Researchers found abnormally high brain activation in individuals without diagnosed Alzheimer's but with memory concerns, suggesting a potential biomarker. Hyperactivation in certain regions increases before cognitive impairments and neuronal loss associated with the disease.
Researchers found that half of patients' cognition worsened after orthopedic surgery, with those having abnormal amyloid-β levels exhibiting memory problems consistent with AD. The study suggests pre-surgical evaluation should include cognitive tests and Alzheimer's biomarker analysis to assess potential brain effects.
A new study has made a significant discovery about the origins of TAU protein in Alzheimer's disease, revealing its primary emergence in the rhinal cortex. The automated method, which tracks TAU buildup using PET imaging, suggests targeting this area could slow disease progression.
University of Kentucky researchers discovered that low blood amylin levels may protect against Alzheimer's disease progression, suggesting a potential therapeutic target. The study found that modulating blood amylin levels could improve cognitive decline and slow the disease.
Researchers have identified microRNA biomarkers that play a role in brain damage caused by traumatic brain injury, and are also associated with Alzheimer's disease. The study found coordinated miRNA dysregulation followed by increased amounts of BACE1, a key enzyme in neurodegenerative disease pathology.
A team of researchers used machine learning to predict how proteins change shape and developed a new approach to study disordered proteins. They found that a key protein implicated in Alzheimer's disease becomes less toxic when it adopts a highly disordered shape.
A study published in Neurology found that individuals with primary progressive aphasia, often associated with Alzheimer's disease, may not develop memory problems. Instead, their language skills decline significantly over time.
Researchers from the University of Gothenburg developed a cheap blood test that can detect Alzheimer's disease earlier than current methods. The test analyzes phosphorylated tau protein levels in blood and shows potential for predicting and monitoring disease progression.
Researchers found a strong correlation between following the MIND and Mediterranean diets and later onset of Parkinson's disease in women up to 17.4 years and men up to 8.4 years. The study suggests nutrition could potentially delay the disease.
Researchers found that approximately half of AD cases are mild, while one-fifth are severe. Early intervention in the mild stage is crucial to slow decline and prevent progression.
Hydrogen sulfide has been shown to improve cognitive and motor function in mice with Alzheimer's disease by 50%. The compound reversed behavioral outcomes of the disease. Research also revealed a change in enzyme activity that could lead to new therapies.
Researchers at Rush University Medical Center found that including unhealthy foods in an otherwise healthy Mediterranean diet may reduce cognitive benefits. The study analyzed data from 5,001 older adults and found that those who followed a Western diet had no beneficial effect on slowing cognitive decline.
Researchers have found that a protein called transthyretin (TTR) can break toxic amyloid beta clumps associated with Alzheimer's disease. The study suggests that modified TTR peptides may prevent or slow progression of the disease in mouse models, offering new hope for patients.
Researchers at Mount Sinai identified three major molecular subtypes of Alzheimer's disease using RNA sequencing data from over 1,500 brain samples. These subtypes were independent of age and disease stage and corresponded to different combinations of dysregulated biological pathways leading to brain degeneration.
Researchers have identified brain cells most susceptible to Alzheimer's disease, which could lead to targeted treatments to boost the brain's resilience. The study found that RORB-expressing neurons are among the first to die in the disease, accumulating tau tangles earlier than neighboring cells.
Researchers developed a blood test that detects misfolded proteins in blood, predicting Alzheimer's disease risk in people with subjective cognitive decline. The test identified those at high and low risk, providing hope for early-stage treatment.
A global research consortium is proposed to collect and share digital speech and language data to detect early signs of Alzheimer's. The consortium aims to create a comprehensive, harmonized repository of samples from diverse cohorts to develop biomarkers that can monitor disease progression.
A century of data suggests SARS-CoV-2's expected long-term effects on the brain and nervous system will have chronic consequences on quality of life and independence. The study, funded by the Alzheimer's Association, aims to understand how COVID-19 increases risk of neurodegenerative diseases like Alzheimer's and psychiatric conditions.
A study found associations between retinal changes and memory problems in older people with type 1 diabetes. Researchers used routine eye scans to detect structural changes in the retina that may be linked to cognitive decline. The findings could lead to better understanding, diagnosis, and treatment of Alzheimer's disease and other co...
Researchers at Trinity College Dublin identify genetic mutations linked to ultra-rare condition ALSP, revealing that dysfunctional white blood cells drive brain damage and BBB breakdown. The study's findings may pave the way for targeted therapies for other forms of dementia.
Researchers have found a specific Alzheimer's treatment effective in male mice but not female mice, highlighting the need for sex-specific design in clinical trials. The study suggests that drugs may work differently in males and females, leading to potentially ineffective treatments for women.
A new study finds that hearing loss and high blood sugar are associated with poor cognitive performance among middle-aged and older Latinos. The research, published in JAMA Otolaryngology-Head & Neck Surgery, suggests that evidence-based interventions, such as hearing aid use, may help mitigate this risk.
Researchers developed a molecule that regulates copper circulation in the brain, extracting trapped copper from amyloid plaques. Administered to Alzheimer's mice, it inhibits memory loss and has shown promise in non-transgenic models closest to human reality.
Researchers found that the ECSIT protein regulates the behavior of proteins linked to energy activity in mitochondria, which are affected in Alzheimer's disease. The team also discovered a link between mitochondrial dysfunction, amyloid accumulation, and early disease symptoms.
Researchers found that YKL-40 is regulated by clock genes and involved in clearing away Alzheimer's proteins in the brain. People with lower levels of YKL-40 fare better in terms of cognitive decline, suggesting it may be a potential therapeutic target.
Researchers found that testing long-term memory recall predicted cognitive decline in healthy older people more accurately than classic memory tests. The study also showed that combining this test with an MRI brain scan improved accuracy in predicting Alzheimer's disease risk.
Researchers at Karolinska Institutet identified two alternative pathways for amyloid pathology in Alzheimer's disease, revealing genetic explanations for method discrepancies. The study provides unique biological information for earlier and more individualized diagnosis and treatment.
A preclinical study by University at Buffalo researchers has identified new genes that could be key therapeutic targets for treating Alzheimer's disease. The study found that inhibiting certain enzymes involved in abnormal gene transcription can reverse memory deficits associated with the disease.
Researchers found that higher baseline NT1 levels in blood samples predicted the risk of cognitive decline and Alzheimer's disease dementia. The study used a cohort of cognitively normal older adults and showed that NT1 levels could be measured before enrollment in AD prevention trials.
A new compound has been identified that targets imidazole I2 receptors to reduce neuroinflammation and improve cognition in late-onset Alzheimer's disease. The study also reveals the calcineurin pathway as a key mechanism of action, opening up possibilities for new therapies.
Alzheimer Europe's new report highlights the need to prioritize dementia research and policy in the EU. The organization recommends allocating fair resources to existing programs, prioritizing dementia within chronic diseases policies, and recognizing it as a disability.
A novel form of an Alzheimer's protein found in spinal fluid indicates what stage of the disease a person is in and tracks with tangles of tau protein in the brain, which are toxic to neurons. The discovery could lead to better diagnostics and accelerate efforts to find treatments for Alzheimer's disease.
Researchers used focused ultrasound to improve delivery of IVIg to the hippocampus, increasing antibodies and neurogenesis by four-fold in a mouse model of Alzheimer's. This technique may help boost the efficacy of immunotherapy for AD treatment.
Researchers at Case Western Reserve University have discovered a new pathway in Alzheimer's disease that could lead to earlier and more effective treatments. The Drp1-HK1-NLRP3 pathway plays a key role in disrupting normal brain cell function, leading to cognitive deficits and degeneration of white matter.
Researchers at Scripps Research have discovered a previously unknown biochemical cascade in the brain that leads to the destruction of synapses in Alzheimer's disease. The study found that abnormal chemical reactions, termed 'protein transnitrosylation reactions,' contribute to synapse loss.
The Alzheimer's Association, Global Brain Health Institute, and Alzheimer's Society have partnered to fund 23 small-scale pilot projects addressing global challenges in dementia. These projects focus on innovative approaches to awareness, diagnosis, treatment, and care for individuals with Alzheimer's disease and other dementias.
A study published in Proceedings of the National Academy of Sciences reveals that liquid-liquid phase separation facilitates tau protein aggregation, a hallmark of neurodegenerative disorders. The researchers discovered a novel regulatory mechanism involving different variants of tau protein, which may influence disease clinical outcomes.
Researchers at Lund University developed an app that predicts Alzheimer's disease risk based on blood biomarker levels, providing a more reliable and accessible early diagnosis method than current cerebral spinal fluid (CSF) analyses.
Researchers analyzed Medicare data to characterize financial presentation of Alzheimer's and related dementias before diagnosis. They found a significant association between the two, suggesting financial errors may be an early indicator of dementia.
An AI model developed at Duke University successfully identified patients with Alzheimer's disease from retinal images, suggesting its potential as a predictive tool. The study provides proof-of-concept for machine learning analysis of certain types of retinal images to detect the neurological disease in symptomatic individuals.
A study published at the University of Exeter Medical School has discovered specialized nerve cells called speed-sensitive cells in the brain's entorhinal cortex that malfunction in Alzheimer's disease. This malfunction disrupts the brain's map, leading to spatial navigation difficulties.
A new study finds that tiny malfunctioning compartments in neurons, called endosomes, are commonly defective in Alzheimer's patients. Endosomal trafficking disruption is associated with high levels of tau proteins in spinal fluid and blood, making it a promising target for developing therapies.
Scientists have developed a new imaging agent using copper isotopes that can effectively detect amyloid-beta protein deposits in the brains of people with Alzheimer's disease. The copper-based compounds outlast traditional diagnostic agents, making it possible for clinics with PET scanners to diagnose the condition more easily.
A new study finds that anxiety is independently associated with cognitive decline and a faster progression to Alzheimer's disease, even in patients without genetic risk factors or brain volume loss. The researchers recommend screening for anxiety disorders in elderly individuals to potentially slow cognitive decline.
Researchers identified new molecular mechanisms driving late-onset Alzheimer's Disease and a promising therapeutic candidate, ATP6V1A, which improved neuronal function when normalized. The study also found potential broad neuroprotective effects for ATP6V1A.
A study led by The Jackson Laboratory and University of Maine found that the expression of Dlgap2 is associated with memory loss in mice and risk for Alzheimer's dementia in humans. Dlgap2 influences the formation of dendritic spines on neurons, which can affect cognitive function.
Researchers propose a two-phase theory for neurodegenerative disorders, with distinct activities of protein signaling pathways in each phase. This understanding could lead to personalized treatment approaches for patients in different stages of the disease.
Researchers found tau accumulation years before dementia symptoms appear in people with Down's syndrome, suggesting an early change. The study suggests potential for early prophylactic measures against tau accumulation to prevent Alzheimer pathology in childhood.
Indiana University researchers will investigate the dynamic between social cognition, social networks and cognitive ability to slow down Alzheimer's progression. The study aims to determine causality and explore how much of the cognitive decline depends on social cognitive function or general cognitive function.
Research reveals that tau protein undergoes stepwise chemical modifications over time, correlating with dementia stage in Alzheimer's disease. The discovery suggests that multiple drugs may be necessary to target tau effectively, with early intervention requiring different therapeutics compared to late-stage treatment.
Research from the University of Eastern Finland explores the role of diabetes in cellular and molecular changes underlying Alzheimer's disease. Diabetes was found to weaken the accumulation of microglial cells around amyloid plaques and increase the formation of neuritic plaques with prominent tau pathology.
A genetic mutation in the Gga3 gene may be more common among African Americans with late-onset Alzheimer's disease, leading to a 'traffic jam' of enzymes in axons. This discovery provides a possible strategy for early diagnosis and targeted treatments, as well as potential biomarkers for detection.
Researchers have discovered that an experimental Alzheimer's disease treatment, PBT2, is effective at disrupting and killing antibiotic-resistant bacteria. The study shows that combining PBT2 with the antibiotic polymyxin successfully tackles superbugs like Klebsiella pneumoniae and Pseudomonas aeruginosa.
Scientists discover a chain reaction leading to Alzheimer's disease starts earlier than thought, triggering toxic protein deposits. An antibody, aducanumab, has been shown to remove seeds of aggregation and reduce brain damage in transgenic mice.
Researchers found that severe reactive astrocytes cause irreversible neurodegeneration and cognitive deficits in just 30 days. Mild reactive astrocytes can reverse their reactivity, but excessive oxidative stress transforms them into neurotoxic severe reactive astrocytes.
Researchers have developed an antibody fragment that reduces Aú peptide and tau protein levels, alleviating cognitive decline and neuroinflammation in advanced Alzheimer's disease models. This breakthrough therapy shows promise as a potential treatment for the devastating disease.
Researchers found that actively speaking two languages contributes to cognitive reserve and delays the onset of symptoms associated with cognitive decline and dementia. Bilingual individuals had a lower risk of developing mild cognitive impairment, which is a preclinical phase of Alzheimer's disease.